BusinessPhoto: Mint MarketsICICI Securities Retains Hold on Sudeep Pharma Despite 75% IPO Surge
Sudeep Pharma shares have risen nearly 75% above their IPO price. However, ICICI Securities believes the current valuation already reflects expectations for its emerging battery materials business. The brokerage maintained a Hold rating and raised the target price to ₹1,000, suggesting cautious optimism for shareholders.
Mint Markets·


